Andra AP fonden Has $16.59 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Andra AP fonden cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.9% in the first quarter, HoldingsChannel reports. The firm owned 29,531 shares of the company’s stock after selling 8,789 shares during the period. Andra AP fonden’s holdings in IDEXX Laboratories were worth $16,593,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Johnson Financial Group Inc. raised its holdings in IDEXX Laboratories by 2,994.4% during the first quarter. Johnson Financial Group Inc. now owns 1,671 shares of the company’s stock valued at $939,000 after buying an additional 1,617 shares in the last quarter. Earned Wealth Advisors LLC boosted its stake in shares of IDEXX Laboratories by 12.4% during the 1st quarter. Earned Wealth Advisors LLC now owns 416 shares of the company’s stock worth $234,000 after acquiring an additional 46 shares in the last quarter. Meeder Asset Management Inc. boosted its stake in shares of IDEXX Laboratories by 19.8% during the 1st quarter. Meeder Asset Management Inc. now owns 151 shares of the company’s stock worth $85,000 after acquiring an additional 25 shares in the last quarter. Meeder Advisory Services Inc. lifted its holdings in IDEXX Laboratories by 1.3% in the 1st quarter. Meeder Advisory Services Inc. now owns 1,896 shares of the company’s stock worth $1,066,000 after purchasing an additional 25 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of IDEXX Laboratories by 4.3% in the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after purchasing an additional 23,582 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Down 2.0%

IDXX opened at $552.46 on Wednesday. The business has a 50 day moving average of $555.50 and a 200-day moving average of $597.62. The stock has a market capitalization of $43.58 billion, a price-to-earnings ratio of 40.68, a P/E/G ratio of 3.08 and a beta of 1.55. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analyst Weigh In

IDXX has been the subject of several recent analyst reports. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Citigroup assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, UBS Group dropped their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.